Gamida Cell Ltd (GMDA) Receives Consensus Rating of “Buy” from Brokerages

Shares of Gamida Cell Ltd (NASDAQ:GMDA) have received an average rating of “Buy” from the five brokerages that are currently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $18.40.

Several equities research analysts recently weighed in on the stock. Needham & Company LLC assumed coverage on shares of Gamida Cell in a research report on Monday, November 26th. They set a “buy” rating and a $23.00 price target for the company. Oppenheimer initiated coverage on shares of Gamida Cell in a research report on Wednesday, November 21st. They issued an “outperform” rating and a $15.00 target price for the company. BMO Capital Markets initiated coverage on shares of Gamida Cell in a research report on Wednesday, November 21st. They issued a “buy” rating and a $19.00 target price for the company. Royal Bank of Canada initiated coverage on shares of Gamida Cell in a research report on Tuesday, November 20th. They issued an “outperform” rating and a $20.00 target price for the company. Finally, CIBC initiated coverage on shares of Gamida Cell in a research report on Wednesday, November 21st. They issued an “outperform” rating and a $15.00 target price for the company.

Shares of GMDA traded down $0.21 on Tuesday, hitting $10.80. 8,289 shares of the stock traded hands, compared to its average volume of 15,265. Gamida Cell has a one year low of $7.99 and a one year high of $15.41.

Gamida Cell Company Profile

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia.

Further Reading: What is the Federal Reserve?

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply